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Abstract 
OBJECTIVE:  The objective of this systematic review is to determine whether or not Actemra 
(tocilizumab) in combination with methotrexate is an effective treatment for rheumatoid arthritis 
in patients who had an inadequate response to methotrexate alone.  Previous studies have shown 
other biologic agents and disease modifying antirheumatic drugs (DMARDs) to have some 
efficacy in treating rheumatoid arthritis.  However, tocilizumab is a newly approved FDA drug 
and therefore, its efficacy in treating RA has yet to be determined. 
 
KEYWORDS:  rheumatoid arthritis, tocilizumab, Actemra, and methotrexate.  
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INTRODUCTION 
 
 Rheumatoid arthritis (RA) is the most common inflammatory arthritis and currently 
affects 1% of the population.
1
  It is predominantly a female condition, but it can also be seen in 
males.  This autoimmune disease is characterized by progressive joint inflammation and damage 
that is symmetric in nature.  Rheumatoid arthritis has a predilection for the small bones of the 
hands and feet including the metacarpal phalanx (MCP), proximal interphalanx (PIP), and 
metatarsal phalanx (MTP) but may also affect the wrists, elbows, knees, ankles, and cervical 
spine.
3
  This disease spares the distal interphalanx (DIP) and the axial skeleton except the 
cervical spine.  The articular signs and symptoms of rheumatoid arthritis include morning 
stiffness lasting greater than 1 hour, joint swelling and tenderness, and limitation of movement.
3
   
Deformities of the hand that are characteristic of RA include swan neck and boutonniere 
deformities.  Extra-articular manifestations that may be seen are fever, fatigue, weight loss, 
anemia, lymphadenopathy, scleritis, episcleritis, pericarditis, vasculitis, amyloidosis, and 
osteoporosis.
3
 
Aggressive treatment is required to treat the chronic and erosive nature of rheumatoid 
arthritis that can eventually lead to joint destruction.  The exact etiology of rheumatoid arthritis is 
unknown, and it is mainly a clinical diagnosis with labs and radiographs used for confirmation.  
Therefore, physician assistants and other health care providers in various fields including family 
medicine, internal medicine, orthopedics, and rheumatology must be adept and prompt in 
diagnosing and treating this condition.  Rheumatoid factor and anti-CCP are positive in 70-80% 
of patients.
3
  Joint space narrowing and joint erosions may be present on radiographs with joint 
erosions indicating late disease and a worse prognosis.
3 
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Treatment for rheumatoid arthritis has targeted the inflammatory system with disease 
modifying antirheumatic drugs (DMARDs) and biologic agents that target specific cytokines.  
The most common DMARD used is methotrexate, which is the first line therapy.
3
  Examples of 
other DMARDs are sulfasalazine and leflunomide.  The biologic agents include etanercept, 
infliximab, adalimumab, and abatacept.  Corticosteroids and over-the-counter nonsteroidal anti-
inflammatory drugs (NSAIDs) may be used as adjuvant therapy.   
The current treatments for rheumatoid arthritis target specific cytokines, including tumor 
necrosis factor α (TNFα) and interleukin 1 (IL-1).1   However, an estimated 20-40% of patients 
do not respond to these regimens even when combined with methotrexate.
1
   It has become 
essential to search for other treatment regimens for rheumatoid arthritis.  Tocilizumab (Actemra) 
is a recent FDA approved drug that targets the cytokine, interleukin 6 (IL-6), which has been 
shown to be increased in the synovial tissue in patients with RA.
4  
 This cytokine causes 
activation of monocytes, neutrophils, T cells, B cells, and osteoclasts, which are all substantially 
involved in the initiation and progression of rheumatoid arthritis
4
.   Targeting interleukin 6 offers 
an alternative treatment regimen for those individuals whose rheumatoid arthritis has been 
resistant to the current treatment modalities.  
OBJECTIVE 
 The objective of this systematic review is to determine whether or not Actemra 
(tocilizumab) in combination with methotrexate is an effective treatment for rheumatoid arthritis 
in patients who had an inadequate response to methotrexate alone.  Previous studies have shown 
other biologic agents and disease modifying antirheumatic drugs (DMARDs) to have some 
efficacy in treating rheumatoid arthritis.  However, tocilizumab is a newly approved FDA drug 
and therefore, its efficacy in treating RA has yet to be determined. 
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METHODS 
The three studies that are included in this review are double-blind randomized controlled 
trials comparing tocilizumab plus methotrexate to a placebo plus methotrexate for the treatment 
of rheumatoid arthritis.  Tocilizumab was given as 2, 4 or 8 mg/kg in the Maini study and as 4 or 
8 mg/kg in the Smolen and Emery studies.  The study population was adult patients with active 
rheumatoid arthritis who had an inadequate response to methotrexate.   The reduction in the 
number of swollen and tender joints was the outcome measured using the ACR20 response rate 
as the primary efficacy endpoint and ACR50 and ACR70 response rates as secondary efficacy 
endpoints. 
These studies were found by the author using Ovid, MEDLINE, and Cochrane databases.  
The key words rheumatoid arthritis, tocilizumab, Actemra, and methotrexate were used in the 
literature searches to find English articles published in peer-reviewed articles dated 2006 to the 
present.  The articles were chosen if they were relevant, valid, and the outcomes of the studies 
mattered to the patients (Patient Oriented Evidence that Matters or POEMS).  The selected 
studies were those that abided by the following set of criteria: POEM, randomized controlled 
trial, a diagnosis of rheumatoid arthritis according to the American College of Rheumatology 
revised criteria, active rheumatoid arthritis for 6 months or more, a swollen joint count of 6 or 
more, and a tender joint count of 8 or more.  The studies that did not meet all of these 
requirements were excluded from this review.  The statistics that are reported are p-values, 
numbers needed to treat (NNT), relative risk reduction (RRR), absolute risk reduction (ARR), 
control event rate (CER), and experimental event rate (EER).  Table 1 shows the demographics 
of the three studies included in this review. 
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Table 1. Demographics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion Criteria WD Interventions 
Emery, 
2008 
(1) 
Double 
blind 
RCT 
499 >18 Active RA >6 
months, swollen 
joint count >6, 
tender joint count 
>8, CRP >1 or 
ESR >28, treated 
with MTX for 
>12 weeks  
Uncontrolled medical 
conditions, other 
inflammatory disease, 
malignancy, 
infection, 
immunodeficiency, 
Hgb <8.5, 
leucopenia, 
thrombocytopenia, 
neutropenia, 
abnormal LFTs, 
triglycerides >10, 
active TB, hepatitis 
B, hepatitis C 
 
568 Tocilizumab 4 or 
8 mg/kg IV q 4 
weeks plus 
methotrexate 
once weekly 
Maini, 
2006 
(2) 
Double 
blind 
RCT 
200 >18 Active RA >6 
months, swollen 
joint count >6, 
tender joint count 
>6, CRP >1 or 
ESR >28, showed 
inadequate 
response to MTX 
during a 
minimum of 6 
months of therapy 
 
Leucopenia, 
neutropenia, 
thrombocytopenia, 
abnormal LFTs, 
received DMARD 
other than MTX 
within 4 weeks prior 
to study, received 
anti-TNF agents 
within 12 weeks or 
leflunomide within 6 
months of infusion of 
study medication  
 
29 Tocilizumab 2, 4, 
or 8 mg/kg IV q 4 
weeks plus 
methotrexate 
once weekly 
Smolen, 
2008 
(3) 
Double 
blind 
RCT 
623 >18 Swollen joint 
count >6, tender 
joint count >8, 
CRP >10 or ESR 
>28, received 
MTX for >12 
weeks 
Autoimmune 
diseases, significant 
systemic involvement 
secondary to RA, 
previous infection, 
hepatitis B, hepatitis 
C, recurrent herpes, 
abnormal chest x-ray, 
previous unsuccessful 
treatment with anti-
TNF agents 
 
57 Tocilizumab 4 or 
8 mg/kg IV q 4 
weeks plus 
methotrexate 
once weekly 
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OUTCOMES MEASURED 
The primary outcome measured in all three studies was the ACR20 response.  This is a 
scale established by the American College of Rheumatology.  An ACR20 response requires a 
patient to have a 20% reduction in the number of swollen and tender joints.  In addition, a 20% 
reduction must be seen in 3 out of 5 other parameters including physician global assessment of 
disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or 
erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire 
(HAQ) score.  The parameter that will be the focus of this review is the number of swollen and 
tender joints.  Secondary endpoints that were measured include the ACR50 and ACR70 response 
rates which require a 50% and 70% reduction in the number of tender and swollen joints, 
respectively.  The two studies by Smolen and Emery measured these outcomes at week 24 where 
as Maini measured the same outcomes at week 16. 
RESULTS 
 All three double-blind randomized controlled trials used the ACR20 response as the 
primary efficacy endpoint.  This endpoint was analyzed by intention to treat.  In the Maini study, 
participants received tocilizumab at 2, 4, or 8 mg/kg plus methotrexate or a placebo plus 
methotrexate.  In both the Smolen and Emery studies, participants received tocilizumab at 4 or 8 
mg/kg plus methotrexate or a placebo plus methotrexate.  All participants received tocilizumab 
or a placebo every 4 weeks and methotrexate every week.  In addition, folic acid was 
administered weekly to each participant to minimize methotrexate-related toxicity.  In order to be 
included in each of these studies, participants were required to have moderate to severe active 
RA for at least 6 months (defined as > 6 tender joints and > 6 swollen joints, an ESR > 28 
mm/hr, and/or an CRP > 1 mg/dl) and to have had an inadequate response to methotrexate or 
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another DMARD.  The Smolen study had the largest number of participants with 623 enrolled 
and 566 completing the study.  499 participants were enrolled in the Emery study with 418 
completing the study.  Lastly, the Maini study had 200 participants enrolled with 171 completing 
the study. 
 The ACR20 response was used as the primary efficacy endpoint, which is defined by the 
American College of Rheumatology as the number of participants with a 20% reduction in the 
signs and symptoms of rheumatoid arthritis.  Smolen and Emery measured the ACR20 response 
at 24 weeks, where as Maini measured it at week 16.   
Table 2. Percentage of participants who achieved an ACR20 response 
Study Placebo + MTX 
(control group) 
Tocilizumab  
2 mg/kg + MTX 
Tocilizumab  
4 mg/kg + MTX 
Tocilizumab  
8 mg/kg + MTX 
Smolen 26% 
 
--- 48% 59% 
Emery 
 
10.1% --- 30.4% 50% 
 
Maini 
41% 64% 63% 74% 
MTX = Methotrexate, NR = Not Reported 
Table 2 shows the percentage of participants who achieved an ACR20 response at week 24 in the 
Smolen and Emery studies and at week 16 in the Maini study.  In all three studies, significantly 
more participants receiving tocilizumab 8 mg/kg had achieved an ACR20 response compared to 
other doses of tocilizumab as well as to a placebo with p-values < 0.001.  Additionally, those 
receiving 2 mg/kg or 4 mg/kg of tocilizumab achieved an ACR20 response that was significantly 
more than those receiving a placebo.  The p-values for the 4 mg/kg groups in the Smolen, Emery, 
and Maini studies were < 0.001, <0.001, and <0.05 respectively.  The p-value for the 2 mg/kg 
group in the Maini study was <0.05.   
 Since all of the results were presented as dichotomous data, they were left in this form to 
be analyzed.  First, the control event rate (CER) and the experimental event rate were calculated.  
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The CER is the percentage of participants who responded to the placebo plus methotrexate and 
the EER is the percentage of participants who responded to the intervention (tocilizumab plus 
methotrexate).  The CER and EER could then be used to calculate the absolute benefit increase 
(ABI) and the relative benefit increase (RBI).  The ABI is the increase of a good event as the 
result of tocilizumab plus MTX.  The RBI is the proportional increase in the rates of good 
outcomes between the experimental and control groups.  The number needed to treat (NNT) was 
then calculated by dividing the absolute risk reduction into 1.  This result indicates the number of 
patients with rheumatoid arthritis that need to be treated with tocilizumab plus methotrexate in 
order to achieve an ACR20 response indicating a reduction in the number of swollen and tender 
joints.  Table 3 below shows the results of the dichotomous data analysis for each of the three 
studies.  In the Emery study, only 3 patients need to be treated in order to achieve one ACR20 
response where as in both the Smolen and Maini studies, 4 patients need to be treated.  However, 
these numbers needed to treat are very similar, indicating similar results among the three studies. 
Table 3. Treatment analysis for patients receiving tocilizumab plus methotrexate vs placebo plus 
methotrexate for rheumatoid arthritis  
Study # completed 
study 
CER 
(placebo + 
MTX) 
EER 
(8 mg/kg 
tocilizumab 
+ MTX) 
ABI RBI NNT 
Smolen 
 
566 26% 59% 33% 227% 4 
Emery 
 
418 10.1% 50% 39% 495% 3 
Maini 
 
171 41% 74% 33% 180% 4 
CER = Control Event Rate, EER = Experimental Event Rate, ABI = Absolute Benefit Increase, 
RBI = Relative Benefit Increase, NNT = Number Needed to Treat, NR = Not Reported  
 
ACR50 and ACR70 response rates were the secondary efficacy end points of the studies and the 
results are summarized in tables 4 and 5 respectively.  These response rates are the percentage of 
participants who had a 50% (ACR50) or 70% (ACR70) reduction in the signs and symptoms of 
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rheumatoid arthritis.  In the Maini study, only the 8 mg/kg group had statistically significant 
achievement of both ACR50 and ACR70 responses when compared to methotrexate alone with a 
p-value < 0.05.  Emery showed a statistically significant achievement of ACR50 and ACR70 
responses in the 8 mg/kg group with p-values of p< 0.001 and p = 0.001 respectively when 
compared to the control group.  For the 4 mg/kg group, only the ACR50 response was 
statistically significant when compared to the control group with a p-value <0.001.  Lastly, the 
Smolen study demonstrated that significantly more participants in both tocilizumab groups had 
ACR50 and ACR70 responses than those in the control group (p-value < 0.001). 
Table 4. Percentage of participants who achieved an ACR50 response 
Study Placebo + MTX 
(control group) 
Tocilizumab  
2 mg/kg + MTX 
Tocilizumab  
4 mg/kg + MTX 
Tocilizumab  
8 mg/kg + MTX 
Smolen 11% 
 
--- 31% 44% 
Emery 
 
3.8% --- 16.8% 28.8% 
Maini 
 
29% 32% 37% 53% 
MTX = methotrexate 
 
Table 5. Percentage of participants who achieved an ACR70 response 
Study Placebo + MTX 
(control group) 
Tocilizumab  
2 mg/kg + MTX 
Tocilizumab  
4 mg/kg + MTX 
Tocilizumab  
8 mg/kg + MTX 
Smolen 2% 
 
--- 12% 22% 
Emery 
 
1.3% --- 5% 12.4% 
Maini 16% 
 
14% 12% 37% 
MTX = methotrexate 
DISCUSSION 
Tocilizumab (Actemra) is a humanized monoclonal antibody that targets interleukin-6 
(IL-6) and prevents it from binding to the interleukin-6 receptors on cell surfaces.
2
   This 
mechanism of action is important because in recent research, interleukin-6 has been shown to be 
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a key cytokine in the initiation and progression of joint inflammation and destruction.  Tumor 
necrosis factor α and interleukin-1 have been the cytokines targeted thus far with rheumatoid 
arthritis therapies without maximum efficacy.  Tocilizumab was approved in the United States by 
the FDA on January 8, 2010 for the treatment of moderate to severe rheumatoid arthritis after an 
inadequate response to methotrexate or other DMARD.
5
  The cost for tocilizumab is estimated to 
be between $1,060 and $2,125 per month.
5
  Currently, there are no contraindications listed by the 
manufacturer.
6   
However, fatal infections including tuberculosis and invasive fungal, bacterial, 
viral, and protozoal infections are listed as a black box warning.  It is important to note that most 
of these infections are found in patients who are using immunosuppressive therapy 
concurrently.
6
   
There are minimal limitations to the three trials included in this systematic review.  All 
three studies can be termed valid for the following reasons.  They were randomized controlled 
trials, the outcomes were presented as dichotomous data, and the patients, clinicians, and study 
workers were blinded to the treatment.  Additionally, losses to follow-up were less than 20% 
with the calculated numbers being 16.2% lost in the Emery study, 9.1% lost in the Smolen study, 
and 16.7% lost in the Maini study.  The initial sample size in the Maini study was small 
compared to the number of participants in the Emery and Smolen studies, 200, 499, and 623 
respectively.  Therefore, the smaller sample size in the Maini study may have affected the 
results.  
CONCLUSION 
 The systematic review of the three randomized controlled studies indicates that 
tocilizumab in combination with methotrexate is an effective treatment option for patients that 
have had an inadequate response to methotrexate alone.  Optimum doses of tocilizumab have 
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been shown to be 4 mg/kg and 8 mg/kg.  Dosing at 2 mg/kg was not proven to be statistically 
significant compared to the control group in the Maini study.  Doses higher than 8 mg/kg have 
not been investigated and should therefore be avoided until further investigation is completed.  
The 6 month time frame used in each of these studies seemed adequate to evaluate the efficacy 
of tocilizumab, but future studies should incorporate observation of long term clinical 
improvement and/or deterioration of patients’ rheumatoid arthritis.  Additionally, only one of the 
studies was conducted in Europe and North America so future studies are needed to assess the 
efficacy of tocilizumab in patients with rheumatoid arthritis in the United States. 
